Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.
Ariela K HolmerRobert BattatParambir S DulaiNiels Vande CasteeleNghia NguyenAnjali JainAra MirallesJennifer NeillHelen LeSiddharth SinghJesus Rivera-NievesWilliam J SandbornBrigid S BolandPublished in: Therapeutic advances in gastroenterology (2020)
In all vedolizumab-treated CD patients, s-MAdCAM-1 decreased significantly and s-α4β7 increased. However, higher concentrations of s-ICAM-1 and s-VCAM-1 at week 6 and lower concentrations of s-α4β7 at week 14 differentiated patients who achieved endoscopic remission. These findings may help identify early predictors of response to vedolizumab treatment in patients with CD. Further validation in less refractory CD patients is needed.